Chia CW, Egan JM (2008) Incretin-based therapies in type 2 diabetes mellitus
Yes, studies show fewer heart attacks and strokes in users
GutGard
PMCID: PMC5990155 ) Prez E, Martnez-Tadeo J, Callero A, Hernndez G, Rodrguez-Plata E, Garca-Robaina JC (2014) A case report of allergy to exenatide
Additionally, there were more deaths in the Tirzepatide group than semaglutide (12 vs 1)
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon